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The International Atomic Energy Agency (IAEA): 
together against cancer
The IAEA was set up in 1957 as the world’s center for 
cooperation in the nuclear field (1). It works with its 
Member States and multiple partners worldwide to promote 
the safe, secure and peaceful use of nuclear technologies. 
While the IAEA was initially established in response to 
the deep fears and great expectations arising from the 
discovery of nuclear energy, its programs that have brought 
the greatest benefit to developing countries include those 
related to the use of radiation in human health. The 
contribution of the IAEA in the treatment of cancer with 
radiotherapy can be dated back to 1958 when its Division of 
Life Sciences began to support the applications of radiation 
in medicine, dosimetry, the environment and radiobiology. 
In the past five decades, its works have been shifting from 
basic research in radiation biology to the design and 
provision of clinical radiation facilities, especially in low- 
and middle-income countries (LMICs). Since 1990, the 
main focus of the program has been health care solutions 
in developing countries ranging from the design of national 
strategies for cancer diagnosis and therapy to procurement 
of equipment and training of essential staff (2,3). Through 
the Program of Action for Cancer Therapy (PACT), 
IAEA has conducted more than 70 impact missions in 
LMICs and mobilized more than €30 million to improve 
cancer diagnosis and treatment in the 10 years since its 
establishment. The imPACT Review, a cancer control 
assessment tool, provides an evaluation of a country’s 
readiness to implement cancer control programs to meet 
the cancer crisis. The Advisory Group on Increasing 
Access to Radiotherapy Technology (AGaRT) and Virtual 
University for Cancer Control (VUCCnet) are remarkable 
programs under the PACT umbrella. The former brings 
together radiotherapy equipment suppliers and radiotherapy 
users from developing countries to ensure that radiotherapy 
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technology is tailored to meet their service requirements. 
The latter program addresses the drastic shortage of 
accessible knowledge and quality training for cancer control 
by using e-learning and traditional teaching approaches 
to develop human resources in cancer control. Apart from 
these, the Technical Cooperation Program is uniquely 
positioned to support relevant and comprehensive cancer 
control proposals submitted by the Member States in 2-year 
planning cycles (4).
One example of the attempts by IAEA to improve 
treatment outcomes is a prospective randomized trial 
conducted to evaluate the addition of a brachytherapy 
boost in patients with advanced nasopharyngeal cancer 
(NPC) treated by standard chemoradiotherapy in 
participating centers from Egypt, Algeria, Morocco, 
Pakistan and Thailand (5). The study did not demonstrate 
a significant improvement in local failure-free survival by 
adding brachytherapy. However, it revealed the important 
observation that local control was poor in these centers, 
even in patients with T1-2N+ disease (3-year local failure-
free survival was 58% with brachytherapy vs. 52% without 
brachytherapy, P=0.34). 
NPC: an ideal model for studying RT access 
NPC has a much skewed geographical and ethnic 
distribution. According to the epidemiological data from 
GLOBOCAN 2012 by the International Agency for 
Research on Cancer (IARC), around 80% of new cases 
occurred in Asia with another 10% in Africa. Indeed the top 
five countries that had the highest number of new cases of 
NPC (China, Indonesia, Vietnam, India and Malaysia) were 
all Asian countries and together they accounted for nearly 
70% of the global burden (Figure 1) (6). 
NPC is one of the most challenging cancers because 
of its highly malignant natural behavior and anatomical 
proximity to critical structures. Radiotherapy is the primary 
treatment modality; the best quality radiotherapy is needed 
to ensure accurate delivery of high-dose radiation to the 
whole tumor extent with maximum protection of normal 
structures. Chemotherapy is added for patients with 
advanced loco-regional disease, as this confers an absolute 
benefit of 6.3% in 5-year overall survival (HR 0.79, 95% 
CI, 0.73–0.86, P<0.0001) (7). Surgery is mainly used for 
diagnosis and salvage of recurrent diseases.
In addition to the requirement for precise, conformal 
radiotherapy, the best quality imaging to delineate the tumor 
extent is crucial. Advancements in imaging techniques, 
in particular the increasing availability of MRI, have also 
contributed to the steady improvement in treatment results. 
A study on the evolution of treatment of NPC showed that 
5-year overall survival increased from around 70% in the 
2-dimensional radiotherapy era in the 1990s to over 80% in 
the contemporary intensity-modulated radiotherapy era (8). 
Unfortunately, there is wide variation in treatment 
outcomes for NPC and health care resources in different 
countries. Most of the countries with the highest number 
of new NPC cases were low-income or low-middle-income 
countries as defined by the World Bank (6,9), and their 
outcomes remain disappointingly poor. Recent reports from 
a center in Yogyakarta of Indonesia showed an alarming 
median overall survival of only 21 months (10). Another 
retrospective study of patients treated with radical chemo/
radiotherapy in Iran showed similar poor results with 2-year 
overall survival of only 35% (11). 
The reasons for the poor outcomes in the LMICs are 
multifactorial. Both the quantity and quality of radiotherapy 
services are key contributing factors. The association 
between socio-economic status and the availability of 
radiotherapy equipment is well-documented in LMICs (12); 
there is a wide variation in radiotherapy resources even 
within Europe. As shown in the ESTRO-HERO survey, 
the access to radiotherapy facilities amount to 7 to 8- fold 
difference across Europe: the number of MV machines per 
million population ranged from 1.4 to 9.5 (median 5.3) (13). 
In an attempt to demonstrate the correlation between 
the access to radiotherapy and treatment outcomes of NPC 
at a global level, we have extracted the epidemiologic data 
from GLOBOCAN and the radiotherapy resource data 
from the Directory of Radiotherapy Centers of the IAEA 
(IAEA-DIRAC). There is a wide variation in access to 
Figure 1 Epidemiological pattern of NPC: incidence in different 
continents with breakdown of the top five countries (Data from 
GLOBOCAN 2012). NPC, nasopharyngeal cancer.
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radiotherapy around the world: the number of radiotherapy 
equipment units ranges from 0.02–12.6 (median 1.6) 
per million populations. Using the [1-(age-standardized 
mortality rate/age-standardized incidence rate)] as the 
proxy relative survival, 112 countries were categorized into 
Poor, Median and Good Outcomes Groups. Our analyses 
showed significant correlation between treatment outcomes 
and the access to radiotherapy. Sadly only 18% of Asian 
countries and 5% of African countries had Good Outcome 
as compared to 53% in Europe (14).
Besides the availability of radiotherapy equipment, access 
to good quality radiotherapy is equally crucial. Modelling of 
Quality Assurance in Radiotherapy (QART) in an EORTC 
head and neck cancer study has suggested clinical benefit 
from increasing QART and that this approach is cost-
effective (15). An analysis from a multi-centre international 
trial on other head and neck cancers has demonstrated that 
better protocol compliance is associated with significantly 
improved outcomes in comparison to cases with a major 
protocol violation: the absolute magnitude of improvement 
amounted to over 20% in 2-year loco-regional failure rate 
(46% vs. 22%) and overall survival (70% vs. 50%) (16). 
Investing in cancer control in LMICs: no longer 
an option, but a responsibility
Since good quality radiotherapy planning is a fundamental 
part of providing a good quality radiotherapy service, the 
IAEA has taken the pioneer role to launch a coordinated 
research project to improve the treatment outcomes of 
NPC patients in the LMICs. Firstly, a national survey will 
be conducted to gather updated demographic data and 
radiotherapy access in the targeted LMICs which have 
a relatively high incidence of NPC but poor treatment 
outcomes (Figure 2). Secondly, a cross-sectional study on 
the characteristics of NPC patients and detailed pattern of 
care in participating centers will be performed. Thirdly, a 
comparative study on quality of RT planning and clinical 
outcomes before and after an educational intervention and 
establishment of local quality control will be conducted. 
Participating centers will be required to submit radiotherapy 
datasets that contain clinical details, the radiotherapy plan 
and prescription for consecutive patients in two phases. The 
submissions will be reviewed by a review panel composed of 
international experts. The first phase (group A) will provide 
baseline information about the quality and practice in the 
participating centers; feedback will be given only if serious 
deviation is noted. Technical evaluation of the baseline 
plans will be summarized and an Educational Workshop 
will then be conducted ‘to train the trainer’ to improve 
their knowledge and skills in RT planning and to establish 
Independent Local Review Team. In the second study phase 
(group B), the radiotherapy plans should be reviewed first 
by the Local Review Team and corrections (if necessary) 
implemented. The intended plan will then be submitted to 
the expert panel for review and feedback will be given as 
quickly as possible to minimize deviation. To prove whether 
the review process and educational intervention translates 
Figure 2 Schematic diagram of the current IAEA proposal in LMICs. IAEA, International Atomic Energy Agency; LMICs, low- and 
middle-income countries.
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into clinical benefits, the quality of radiotherapy planning 
and treatment outcomes will be compared between the 
two groups. Through this study, it is earnestly hoped that a 
robust practical model can be established and international 
collaboration can be enhanced to bring about a sustainable 
improvement in radiotherapy services in the LMICs.
Conclusions
One of the missions of IAEA is to harness the power of 
radiation for the greatest benefit in health care. A major 
aspect is to help LMICs to develop national strategies 
for cancer diagnosis and therapy, procure equipment and 
train essential staff. NPC is highly curable by good quality 
radiotherapy, but currently the outcomes remain poor 
in LMICs where this peculiar cancer is most prevalent. 
This project will be an ideal model for studying access 
to radiotherapy and improving quality control through 
educational intervention. It is earnestly hoped that 
concerted global efforts will improve equity of access to 
universal, high quality radiotherapy and hence improve 
outcomes for patients with NPC.
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